1. Home
  2. CANF

as of 01-15-2026 3:57pm EST

$4.23
$0.06
-1.40%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

Founded: 1994 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 3.5M IPO Year: N/A
Target Price: $9750.00 AVG Volume (30 days): 555.6K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -8.88 EPS Growth: N/A
52 Week Low/High: $3.36 - $46.60 Next Earning Date: 02-03-2026
Revenue: $560,000 Revenue Growth: -16.04%
Revenue Growth (this year): 461.72% Revenue Growth (next year): -20.66%

AI-Powered CANF Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 0.00%
0.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: